• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott divests 60% of its stake in Mylan

March 24, 2017 By Sarah Faulkner

Abbott divests 60% of its stake in MylanAbbott (NYSE:ABT) divested 60% of its remaining stake in Mylan (NSDQ:MYL) this week, according to regulatory filings, disposing of 44 million shares at $41.60 apiece. The trade was valued at $1.7 billion.

In 2014, Mylan bought Abbott’s generics business outside the U.S. in a deal that rang in at nearly $5.3 billion. The deal allowed Canonsburg, Penn.-based Mylan to cut its tax bill by moving its tax address outside the U.S., and Abbott received an ownership stake of 21% with 105 million shares of the company.

In the year following the initial deal, Abbott sold off 1/3 of the stock, reducing its stake in Mylan to 15%.

MYL shares were down -2.7% this morning at $40.47 apiece.

Mylan recalled 81,000 EpiPen emergency allergy auto-injectors this week after receiving 2 reports that the device failed to work in emergencies. The recall affects devices in Australia, New Zealand, Europe and Japan, the company reported.

In both cases, patients received treatment using an alternate EpiPen, according to Mylan. The drugmaker also said that it is working with regulatory authorities in affected countries to inform them about the recall.

In February, Abbott touted results today from real-world use data for its FreeStyle Libre blood glucose monitoring system. The data showed that people using its FreeStyle Libre system to monitor their glucose levels spend less time in hypoglycemia or hyperglycemia and have improved average glucose levels.

More than 50,000 diabetes patients using the FreeStyle Libre system checked their glucose levels 16 times a day, on average, according to the data.

The company’s FreeStyle Libre system uses a small sensor worn on the back of the upper arm to measure glucose every minute in interstitial fluid through a filament inserted under the skin. Abbott said its system can produce a glucose reading painlessly in less than 1 second by scanning a reader over the sensor.

Filed Under: Featured, Regulatory/Compliance, Wall Street Beat Tagged With: Abbott Laboratories, Mylan

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS